Financial Statements

Zentalis Pharmaceuticals, Inc. (ZNTL)

$20.73

-0.69 (-3.22%)
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers are in thousands

Retained Earning Schedule

Year 2021 2020 2019 2018
Retained Earnings (Previous Year) -201-83-37-
Net Income -159-118-46-21
Stock Dividends ----16
Dividend Paid ----
Retained Earnings -360-201-83-37

PPE Schedule

Year 2021 2020 2019 2018
Gross PPE 430-
Annual Depreciation 55230
Capital Expenditure -6-1-0-0
Net PPE 53430

Intangible and Goodwill Schedule

Year 2021 2020 2019 2018
Intangible and Goodwill (Previous Year) -444
New Purchases ---401-364
Intangible and Goodwill 4444

Zentalis Pharmaceuticals, Inc. income statement is the only one that provides an overview of company sales and net income
The reasoning behind the adjustment, however, is that free cash flow is meant to measure money being spent right now, not transactions that happened in the past. This makes Zentalis Pharmaceuticals, Inc. FCF a useful instrument for identifying growing companies with high up-front costs, which may eat into earnings now but have the potential to pay off later.